Treatment of metastatic castration resistant prostate cancer with radium-223: a retrospective study at a US tertiary oncology center

BACKGROUND: Guidelines for optimal sequencing of radium-223 and chemotherapy for metastatic castration resistant prostate cancer (mCRPC) do not exist. This study evaluated treatment patterns and overall survival (OS) among patients with mCRPC treated with radium-223 in an academic clinical setting....

Descripción completa

Detalles Bibliográficos
Autores principales: McKay, Rana R., Silver, Rebecca, Bhak, Rachel H., Korves, Caroline, Cheng, Mu, Appukkuttan, Sreevalsa, Simmons, Stacey J., Duh, Mei Sheng, Taplin, Mary-Ellen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8012208/
https://www.ncbi.nlm.nih.gov/pubmed/32814846
http://dx.doi.org/10.1038/s41391-020-00271-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8012208/
https://www.ncbi.nlm.nih.gov/pubmed/32814846
http://dx.doi.org/10.1038/s41391-020-00271-7

Ejemplares similares